The global gastric motility disorder drugs market is undergoing significant evolution, driven by rising gastrointestinal (GI) disease prevalence and increasing patient awareness. Gastric motility disorders, such as gastroparesis, chronic constipation, and irritable bowel syndrome with constipation (IBS-C), are affecting millions worldwide, thereby generating consistent demand for advanced...